Investigation of Serum Amphiregulin Concentrations in Pregnant Women Diagnosed with Isolated Fetal Growth Restriction in the Third Trimester

Abstract

Objective We aimed to investigate serum amphiregulin (AREG) concentrations in pregnant women with isolated fetal growth restriction (FGR) in the third trimester.

Materials and methods This cross-sectional study was conducted with 90 pregnant women who applied to the Umraniye Training and Research Hospital Gynecology and Obstetrics Clinic between January 2022 and May 2022. The FGR group consisted of 45 pregnant women diagnosed with FGR in the third trimester, and the control group consisted of 45 healthy pregnant women matched with the FGR group in terms of age and body mass index (BMI). Demographic characteristics, ultrasound findings, and neonatal outcomes were noted. As a primary outcome, the two groups were compared for maternal serum AREG concentrations.

Results Both groups were similar in terms of demographic characteristics (p>0.05). While fetal BPD, AC, and FL measurements in the group diagnosed with FGR were significantly lower than in the control group, umbilical artery Doppler PI and S/D were higher (p=0.000, for all). Gestational age at birth, newborn birth weight, birth height, and 1-minute Apgar score were significantly lower and the NICU admission rate was higher in the FGR group (p=0.000, p=0.000, p=0.000, p=0.027, p=0.011 respectively). Gestational age at blood sampling for AREG was similar in both groups (p=0.869). While maternal serum AREG concentration was 969.39 ng/L in the FGR group, it was 795.20 ng/L in the control group (p=0.018). AUC analysis of AREG for estimation of FGR in ROC analysis was 0.57 (p<0.247, 95% CI=0.44–0.69). The optimal threshold value for FGR estimation of maternal serum AREG concentration was determined as 874.03 ng/L with 55% sensitivity and 55% specificity.

Conclusion High maternal serum AREG concentrations appear to be associated with isolated FGR in the third trimester. The pathways through which AREG modulates fetal growth remain to be investigated.

Key words

Amphiregulin - epidermal growth factor - fetal growth - fetal growth restriction

Publication History

Received: 10 May 2023

Accepted: 14 July 2023

Article published online:
25 August 2023

• References

• 1 Bendix I, Miller SL, Winterhager E. Editorial: Causes and consequences of ıntrauterine growth restriction. Front Endocrinol 2020; 11: 205
• 2 Sebio A, Páez D, Salazar J. et al. Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. Pharmacogenomics J 2014; 14: 256-262
• 3 Plowman GD, Green JM, McDonald VL. et al. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 1990; 10: 1969-1981
• 4 Peterson EA, Shabbeer S, Kenny PA. Normal range of serum amphiregulin in healthy adult human females. Clin Biochem 2012; 45: 460-463
• 5 Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 2011; 12: 104-117
• 6 Lysiak JJ, Johnson GR, Lala PK. Localization of amphiregulin in the human placenta and decidua throughout gestation: role in trophoblast growth. Placenta 1995; 16: 359-366
• 7 Lees CC, Stampalija T, Baschat AA. et al. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol 2020; 56: 298-312
• 8 Berasain C, Avila MA. Amphiregulin. Semin Cell Dev Biol 2014; 28: 31-41
• 9 Yu Y, Fang L, Wang S. et al. Amphiregulin promotes trophoblast invasion and increases MMP9/TIMP1 ratio through ERK1/2 and Akt signal pathways. Life Sci 2019; 236: 116899
• 10 Fukami T, Yoshizato T, Miyamoto S. et al. Amphiregulin regulates the production of human chorionic gonadotropin in trophoblasts. Life Sci 2009; 84: 796-804
• 11 Fang L, Wang S, Han X. et al. Amphiregulin stimulates human chorionic gonadotropin expression by inducing ERK1/2-mediated ID3 expression in trophoblast cells. Placenta 2021; 112: 73-80
• 12 Menashi S, Serova M, Ma L. et al. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. Cancer Res 2003; 63: 7575-7580
• 13 Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997; 70: 722-726
• 14 Güler Ö, Özer A, Seyithanoğlu M. et al. Serum amphiregulin and cerebellin-1 levels in severe preeclampsia. J Matern Fetal Neonatal Med 2021; 34: 2863-2868
• 15 Bulmer JN, Thrower S, Wells M. Expression of epidermal growth factor receptor and transferrin receptor by human trophoblast populations. Am J Reprod Immunol 1989; 21: 87-93
• 16 Evain-Brion D, Alsat E. Epidermal growth factor receptor and human fetoplacental development. J Pediatr Endocrinol Metab 1994; 7: 295-302
• 17 Magid M, Nanney LB, Stoscheck CM. et al. Epidermal growth factor binding and receptor distribution in term human placenta. Placenta 1985; 6: 519-526